Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug 14;206(9):378.
doi: 10.1007/s00203-024-04104-2.

Recent advances of 3-fucosyllactose in health effects and production

Zhihui Du  1 , Zeyu Li  1 , Cuie Guang  1 , Yingying Zhu  1 , Wanmeng Mu  2
Affiliations
Review

Recent advances of 3-fucosyllactose in health effects and production

Zhihui Du et al. Arch Microbiol. .

Abstract

Human milk oligosaccharides (HMOs) have been recognized as gold standard for infant development. 3-Fucosyllactose (3-FL), being one of the Generally Recognized as Safe HMOs, represents a core trisaccharide within the realm of HMOs; however, it has received comparatively less attention in contrast to extensively studied 2'-fucosyllactose. The objective of this review is to comprehensively summarize the health effects of 3-FL, including its impact on gut microbiota proliferation, antimicrobial effects, immune regulation, antiviral protection, and brain maturation. Additionally, the discussion also covers the commercial application and regulatory approval status of 3-FL. Lastly, an organized presentation of large-scale production methods for 3-FL aims to provide a comprehensive guide that highlights current strategies and challenges in optimization.

Keywords: 3-Fucosyllactose; Commercial application; Health effects; Large-scale production; Regulatory approval.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Agoston K, Hederos MJ, Bajza I, Dekany G (2019) Kilogram scale chemical synthesis of 2’-fucosyllactose. Carbohydr Res 476:71–77. https://doi.org/10.1016/j.carres.2019.03.006 - DOI - PubMed
    1. Alayón S, Varela V, Mukuria-Ashe A, Alvey J, Milner E, Pedersen S, Yourkavitch J (2022) Exclusive breastfeeding: measurement to match the global recommendation. Matern Child Nutr 18(4):e13409. https://doi.org/10.1111/mcn.13409 - DOI - PubMed - PMC
    1. Ammann R (2017) Achieving the impossible: Jennewein Biotechnologie is dedicated to the production of human milk oligosaccharides. Eur Dairy Magazine 29:30–31. https://doi.org/10.1016/j.copbio.2018.11.003 - DOI
    1. Asakuma S, Hatakeyama E, Urashima T, Yoshida E, Katayama T, Yamamoto K, Kumagai H, Ashida H, Hirose J, Kitaoka M (2011) Physiology of consumption of human milk oligosaccharides by infant gut-associated bifidobacteria. J Biol Chem 286(40):34583–34592. https://doi.org/10.1074/jbc.M111.248138
    1. Ashida H, Miyake A, Kiyohara M, Wada J, Yoshida E, Kumagai H, Katayama T, Yamamoto K (2009) Two distinct alpha-L-fucosidases from Bifidobacterium bifidum are essential for the utilization of fucosylated milk oligosaccharides and glycoconjugates. Glycobiology 19(9):1010–1017. https://doi.org/10.1093/glycob/cwp082

LinkOut - more resources